1 BTC
=
- USD
Ionis Pharmaceuticals, Inc. Common Stock
As of June 24, 2026 at 21:24 UTC
Chart
About Ionis Pharmaceuticals, Inc. Common Stock
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
IONS in Bitcoin terms
Ionis Pharmaceuticals, Inc. Common Stock is tracked on Roxom Terminal for users who want to follow and trade global stocks in a Bitcoin-denominated market environment.
- Ionis Pharmaceuticals, Inc. Common Stock is categorized under PHARMACEUTICAL PREPARATIONS.
- BTC-denominated charting frames stock performance against Bitcoin instead of fiat alone.
- The global terminal hub links individual stock pages into a crawlable BTC-native market map.
Market Statistics
Trading Metrics
How to Buy IONS
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy IONS
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesThe global protein synthesis research market is experiencing accelerating growth driven by increased investment in cell and gene therapy research, rising chronic disease prevalence, and expanding healthcare budgets. North America leads with 42.8% market share, while Asia-Pacific infrastructure expansion presents significant growth opportunities. Key market drivers include strong late-stage therapy pipelines and government support through initiatives like the CHIPS and Science Act.
The oligonucleotides clinical trial landscape is expanding rapidly with 200+ companies developing 600+ pipeline drugs. Major players like Novartis, Alnylam Pharmaceuticals, Amgen, and WaVe Life Sciences are advancing promising therapies across various clinical stages. Approximately 20+ oligonucleotides are in late-stage development while 150+ are in mid and early stages. Recent developments include SanegeneBio's $110M Series B funding, FDA approvals for multiple orphan drug designations, and several companies advancing Phase II and Phase III trials.
Biogen stock fell 4.97% after reporting Phase 2 results for its Alzheimer's drug diranersen, which missed its primary endpoint but showed cognitive benefits and tau biomarker reductions across all doses. The company plans to advance the therapy to registrational development. Separately, Biogen completed its acquisition of Apellis Pharmaceuticals, adding two commercial drugs worth $689 million in 2025 revenue.
GSK entered an exclusive strategic collaboration with Sino Biopharmaceutical to accelerate bepirovirsen, an investigational hepatitis B treatment, in mainland China. The drug is under priority regulatory review in China and showed positive Phase 3 trial data. GSK will retain marketing authorization and regulatory responsibility while CTTQ handles distribution and promotional activities. Additionally, GSK announced the final tranche of its £2 billion share repurchase program.
The complement inhibitors market is projected to experience strong growth through 2036, driven by rising prevalence of complement-mediated diseases, increased R&D efforts, and approval of new therapeutic agents. The US represents the largest market, with IgAN showing approximately 135,000 diagnosed prevalent cases. Key emerging therapies from major pharmaceutical companies are expected to expand treatment options across multiple indications including PNH, aHUS, CIDP, and IgAN.
